To determine if daily intake of a formulation containing Bifidobacterium lactis Bl-04™ would have a positive impact in the prevention of upper respiratory tract illness (URTI) episodes
5-month, double-blind, placebo controlled
310 healthy, physically active adults randomized to two treatment groups*:
*An additional probiotic formula was investigated in this study, but results are not reported here.
Evaluation of symptoms and physical activity were conducted via Web-based questionnaire. The signs and symptoms of URTI included a scratchy throat, sore throat, sneezing, stuffy nose, or runny nose. A diagnosis of URTI was made when two or more symptoms were recorded for three or more consecutive days.
Bl-04™ Was Associated With Decreased Risk of URTI Episodes
To study the effect of B. lactis Bl-04™ on innate and adaptive immune responses, and nasal rhinovirus load for 5 days following a rhinovirus challenge infection.
Randomized, double-blind, placebo controlled
115 healthy adults were randomized to two treatment groups:
Markers of immune function (interleukin 8 and other cytokines) and rhinovirus levels were measured from nasal washes as well other endpoints.
Bl-04™ Reduced the Amount of Rhinovirus in Nasal Mucosa
Additional Study Information
West NP, et al. Clin Nutr. 2014;33(4):581-587.
Turner RB, et al. Benef Microbes. 2017;8(2):207-215.
1. West NP, Horn PL, Pyne DB, et al. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr. 2014;33(4):581-587.
2. Turner RB, Woodfolk JA, Borish L, et al. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomized controlled trial. Benef Microbes. 2017;8(2):207-215.